Fluvastatin protects against puromycin aminonucleoside-induced podocyte injury by inhibiting TRPC6

doi:10.5246/jcps.2022.05.031

Abstract

Abstract:

In the present study, we aimed to investigate the effect of puromycin aminonucleoside (PAN) on the expression and distribution of transient receptor potential canonical 6 (TRPC6) of murine podocytes and further study the protective mechanism of fluvastatin on podocyte injury by TRPC6 in vitro. Podocytes were treated by PAN at different doses and at different time points. The expressions of TRPC6 at mRNA and protein levels were assessed. An immunofluorescent assay was used to observe the distribution of TRPC6. Cultured podocytes were then divided into four groups. The expressions of TRPC6 at mRNA and protein levels were measured. The intracellular calcium concentration of podocytes was measured with a laser-scanning confocal microscope. The paracellular permeability to BSA was evaluated using Millicell-PCF Inserts. The expressions of TRPC6 at mRNA and protein levels were increased in a dose and time-dependent manner after exposure to PAN. Immunofluorescence showed that the expression intensity of TRPC6 was significantly increased, and the distribution of TRPC6 was changed after PAN was applied to podocytes. With fluvastatin intervention, PAN-induced up-regulation of TRPC6 was significantly reversed. The ratio of the peak value of intracellular calcium to the basic calcium value in the PAN group was significantly higher after TRPC6 was activated by OAG, while it is obviously reversed under the action of fluvastatin. The podocyte permeability was significantly increased after 48 h of PAN treatment, while the above situation was effectively improved after fluvastatin intervention. The changes of distribution and expression of TRPC6 were related to podocyte injury induced by PAN. Fluvastatin could exert its protective effects on podocytes by down-regulating TRPC6.

Key words: TRPC6, Podocyte, Puromycin aminonucleoside, Fluvastatin, Calcium

Supporting:

Hui Gao, Yunjing Zhang, Jing Lin, Xifeng Sun. Fluvastatin protects against puromycin aminonucleoside-induced podocyte injury by inhibiting TRPC6[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(5): 360-368.

Figures/Tables 6

References 15

[1]	Assady, S.; Wanner, N.; Skorecki, K.L.; Huber, T.B. New insights into podocyte biology in glomerular health and disease. . J. Am. Soc. Nephrol. 2017, 28, 1707–1715.
[2]	Winn, M.P.; Conlon, P.J.; Lynn, K.L.; Farrington, M.K.; Creazzo, T.; Hawkins, A.F.; Daskalakis, N.; Kwan, S.Y.; Ebersviller, S.; Burchette, J.L.; Pericak-Vance, M.A.; Howell, D.N.; Vance, J.M.; Rosenberg, P.B. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science. 2005, 308, 1801–1804.
[3]	Ma, R.; Chaudhari, S.; Li, W. Canonical transient receptor potential 6 channel: a new target of reactive oxygen species in renal physiology and pathology. Antioxid. Redox Signal. 2016, 25, 732–748.
[4]	Zhang, C.; Jiang, H.J.; Chang, Y.; Fang, Z.; Sun, X.F.; Liu, J.S.; Deng, A.G.; Zhu, Z.H. Downregulation of CD2-associated protein impaired the physiological functions of podocytes. Cell Biol. Int. 2009, 33, 632–639.
[5]	Aizawa, K.; Takeda, S.; Tashiro, Y.; Yorozu, K.; Hirata, M.; Kanada, H.; Moriguchi, Y.; Endo, K. Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome. Am. J. Nephrol. 2012, 36, 419–426.
[6]	Wen, D.; You, L.; Zhang, Q.; Zhang, L.; Gu, Y.; Hao, C.M.; Chen, J. Upregulation of nestin protects podocytes from apoptosis induced by puromycin aminonucleoside. Am. J. Nephrol. 2011, 34, 423–434.
[7]	Horikawa, A.; Yoneda, T.; Yaoita, E.; Yamaguchi, K.; Shigenobu, S.; Kuramochi, M.; Yamate, J.; Inui, T.; Ishibashi, O. A novel splicing variant of small nucleolar RNA host gene 4 is a podocyte-selective non-coding RNA upregulated in response to puromycin aminonucleoside-induced podocyte injury. J. Biochem. 2019, 165, 447–454.
[8]	Tsui, C.C.; Shankland, S.J.; Pierchala, B.A. Glial cell line–derived neurotrophic factor and its receptor ret is a novel ligand-receptor complex critical for survival response during podocyte injury. J. Am. Soc. Nephrol. 2006, 17, 1543–1552.
[9]	Jia, H.Y.; Li, Z.N.; Chen, G.L. Effect of transforming growth factor beta 1/Sma- and Mad-related protein signal pathwayin diabetic nephropathy and related drugs: a review. Chin. J. Pharmacol. Toxicol. 2016, 30, 266–271.
[10]	Sun, X.F.; Chu, Y.L.; Zhang, C.; Du, X.Y.; He, F.F.; Chen, S.; Gao, P.; Liu, J.S.; Zhu, Z.H.; Meng, X.F. Effect of TRPC6 knockdown on puromycin aminonucleoside-induced podocyte injury. J. Huazhong Univ. Sci. Technol. [Med Sci]. 2012, 32, 340–345.
[11]	Sun, X.F.; Fang, Z.; Zhu, Z.H.; Yang, X.; He, F.F.; Zhang, C. Effect of down-regulation of TRPC6 on the puromycin aminonucleoside-induced apoptosis of mouse podocytes. J. Huazhong Univ. Sci. Technol. [Med Sci]. 2009, 29, 417–422.
[12]	Chen, S.; He, F.F.; Wang, H.; Fang, Z.; Shao, N.; Tian, X.J.; Liu, J.S.; Zhu, Z.H.; Wang, Y.M.; Wang, S.; Huang, K.; Zhang, C. Calcium entry via TRPC6 mediates albumin overload-induced endoplasmic reticulum stress and apoptosis in podocytes. Cell Calcium. 2011, 50, 523–529.
[13]	Häfner, S.; Urban, N.; Schaefer, M. Discovery and characterization of a positive allosteric modulator of transient receptor potential canonical 6 (TRPC6) channels. Cell Calcium. 2019, 78, 26–34.
[14]	Rogacka, D.; Audzeyenka, I.; Rachubik, P.; Rychłowski, M.; Kasztan, M.; Jankowski, M.; Angielski, S.; Piwkowska, A. Insulin increases filtration barrier permeability via TRPC6-dependent activation of PKGIα signaling pathways. Biochim. Et Biophys. Acta BBA Mol. Basis Dis. 2017, 1863, 1312–1325.
[15]	Vassiliadis, J.; Bracken, C.; Matthews, D.; O'Brien, S.; Schiavi, S.; Wawersik, S. Calcium mediates glomerular filtration through calcineurin and mTORC2/Akt signaling. J. Am. Soc. Nephrol. 2011, 22, 1453–1461.